DUBLIN, Sept. 26, 2018 /PRNewswire/ --
The "Investigation Report on China's Lamivudine Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
At the end of 2017, there were more than 700,000 registered HIV-infected persons and AIDS patients in China. In addition, a large number of people infected with HIV and AIDS patients have not been discovered. Meanwhile, over 90 million people in China are infected with the hepatitis B virus.
Lamivudine is a major drug against the hepatitis B virus and AIDS in China. The Chinese government offers it to AIDS patients for free. Lamivudine is a nucleoside analog as well as an antiviral drug. In 1998, the FDA first approved Lamivudine as a treatment for hepatitis B.
The State Food and Drug Administration (SFDA) approved the drug to be imported to China for the treatment of hepatitis B. In 1999, GlaxoSmithKline started to sell its original Lamivudine in the trade name "Heptodin" in China. More than 2 million hepatitis B patients and an unknown number of HIV-infected patients and AIDS patients are taking Heptodin in China.
By the end of 2017, more than 10 enterprises had been approved to produce Lamivudine tablets or capsules. Lamivudine developed rapidly after it entered China. The sales volume reached CNY 307 million in 2012, declined from 2013 and fell to about CNY 159 million in 2017.
The market is dominated by GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd., Wellcome Foundation, Anhui Biochem Bio-Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. has the largest market share. Its sales value exceeded CNY 100 million in 2017, taking up a market share close to 67%.
Considering the large number of hepatitis B and AIDS patients in China, it is expected that the market size of China's Lamivudine market will continue to grow.
Key Topics Covered:
1 Relevant Concepts of Lamivudine
1.1 Indications for Lamivudine
1.2 Development History of Lamivudine in China
1.3 Governmental Approval of Lamivudine in China
2 Sales of Lamivudine in China, 2013-2017
2.1 Sales Value
2.2 Sales Volume
2.3 Sales of Lamivudine by Dosage Form in China, 2013-2017
3 Analysis on Major Lamivudine Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Lamivudine Manufacturers
3.2 GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd.
3.3 Wellcome Foundation
3.4 Anhui Biochem Bio-Pharmaceutical Co., Ltd.
3.5 Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd.
3.6 Beijing Winsunny Pharmaceutical Co., Ltd.
4 Prices of Lamivudine in China, 2017-2018
4.1 GlaxoSmithkline Pharmaceuticals (Suzhou) Co., Ltd. (Heptodin)
4.2 Wellcome Foundation
4.3 Anhui Biochem Bio-Pharmaceutical Co., Ltd. (Yinding)
4.4 Hunan Qianjin Xiangjiang Pharmaceutical Joint Stock Co., Ltd. (Jianganling)
4.5 Beijing Winsunny Pharmaceutical Co., Ltd. (Winsunny Like)
5 Prospect of China's Lamivudine Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/research/phw6qx/china_lamivudine?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets